Biotechnological advancements in the field of medicine have enabled many researchers to come up with innovative cancer therapies which improve lives of cancer patients. Seattle Genetics, a biotechnology company headed by Dr. Clay B Siegall who is the current President and CEO has been able to come up with an innovative antibody-based therapy for cancer treatment. Having been a co-founder of Seattle Genetics in the year 1998, Siegall has been consistently involved in cancer research. In 2002, Dr. Clay became the company’s CEO and has since been leading his company in making better innovations in the fight against cancer.
Dr. Clay Siegall began his career life in Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator having received his Ph.D. in Genetics from the George Washington University. He had also previously received a B.S. in Zoology from the University of Maryland. Later he got a promotion to become the Principal Scientist in Bristol-Myers. He then moved to the National Cancer Institute where he became a Biotechnology Fellow as well as a Staff Fellow. In this position, Siegall began focusing on the launching of Seattle Genetics Company.
Currently, as the CEO and President of Seattle Genetics, Siegall has helped the company develop the first antibody-drug conjugates such as ADCETRIS which was approved by FDA in 2011. In the year 2012, Siegall was named the Pacific Northwest Ernst and Young Entrepreneur of the year. Later in 2013, he was awarded University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences for his contributions to the scientific and medical communities. Apart from making advancements in medicine, Dr. Clay Siegall also helped in the capital raising activities which secured Seattle Genetics about 1.2 billion dollars.
Siegall has also had other several positions in the company such as the Interim Chairman and later became Director of Ultragenyx Pharmaceutical Inc. from 2014. He is also a Director of Alder Pharmaceuticals Inc since the year 2005. He also serves as the Director of Washington Biotechnology and Biomedical Association and also a director of the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. Clay also recently served as a Non-Executive Director of Mirna Therapeutics, Inc from 2013 to 2016.